Share

The 31st Annual EORTC-PAMM Group Meeting, 28 – 30 January 2010

The 31st Annual EORTC-PAMM Group Meeting will be held 28 – 30 January 2010 in Toulouse, France. The main topic of the meeting will be “Treatment Individualization” and will focus on the different groups of anticancer agents, i.e., drugs interacting with DNA, tyrosine kinases, hormonal receptors, checkpoints, and inhibitors of angiogenesis. The plenary sessions will consist of presentations by invited speakers followed by proffered papers in the same area. There will also be a poster session. The PAMM group has always encouraged the submission of abstracts for presentation, and many of these abstracts will be presented by younger members from established groups across Europe. This meeting will bring together an international audience with a wide range of medical-scientific backgrounds. Both fundamental and clinical work will be presented, and the congress should provide an opportunity for extensive interactions among international experts in cancer treatment and care.

The meeting will be held at the “Museum d’Art Contemporain” located in the center of Toulouse near the bank of the Garonne river and close to the Claudius Regaud Cancer Institute. The social program will provide an opportunity for congress participants to play in the traditional football match between PAMM members. Two dinners are foreseen on two evenings: a relaxed and convivial dinner and a Gala dinner to be held in a castle typical of the South-West of France.

For registration, please contact:
Isabelle Degrave (degrave.isabelle@claudiusregaud.fr) – Phone: 0033 5 61 42 42 32

For information about the program and events please contact :
Ben Allal (allal.ben@claudiusregaud.fr) or Etienne Chatelut (chatelut.etienne@claudiusregaud.fr)

Also at this event, Jean-Pierre Armand, Director of the Claudius Regaud Cancer Institute, will present the Toulouse Canceropole project, a planned 200 hectare campus that will group together professionals involved in the fight against cancer. The Toulouse Cancerpole is both a medically and scientifically ambitious project that will be a first in terms of gathering researchers, engineers, industrialists, physicians and academics all around the patient. It is foreseen that approximately 4 000 professionals will be employed at this site.

John Bean
Valérie Flipo (flipo.valerie@claudiusregaud.fr )

Back to news list

Related News

  • EORTC: Advancing research and treatment for rare cancers

  • EORTC Fellowship Programme: celebrating more than 20 years of impactful collaboration

  • Appointment of Malte Peters as EORTC Strategic Alliance Officer

  • Unique series of workshops in partnership with the European Medicines Agency (EMA)

  • EORTC launches a prominent clinical trial in older patients with locally advanced (LA) HNSCC (Head and Neck Squamous Cell Carcinoma)

  • Seven IMMUcan abstracts selected for ESMO Immuno-Oncology Congress 2023

  • EORTC Quality of Life measures integrated in CDISC

  • EORTC and Immunocore are collaborating to launch the ATOM clinical trial of tebentafusp in Adjuvant Uveal Melanoma

  • Treatment with decitabine resulted in a similar survival and fewer adverse events compared with conventional chemotherapy in older fit patients with acute myeloid leukaemia

  • New results and forthcoming EORTC trials in rare cancers, lung, head and neck, and breast carcinomas presented at ESMO 2023